Triple-Agonist Retatrutide Significantly Reduces Obstructive Sleep Apnea Severity in Phase 3 Trials

Eli Lilly is preparing to ask the US Food and Drug Administration to approve its experimental weight-loss drug retatrutide for obstructive sleep apnea early next year, armed with new Phase 3 data showing the medication drastically cuts nighttime breathing disruptions. The regulatory filing will seek to expand the therapeutic reach of incretin drugs further into sleep medicine.[2]

The clinical results, published October 21 in the New England Journal of Medicine, demonstrate that the once-weekly triple-hormone agonist reduced the apnea-hypopnea index by up to 34.3 events per hour in patients without diabetes. For the average trial participant, that magnitude of improvement shifted their disease classification from severe down to moderate.[5]

"For patients with obesity-related obstructive sleep apnea, achieving meaningful and sustained reductions in disease severity remains challenging, particularly when weight loss is difficult to maintain," noted Physician's Weekly in its clinical review. The data confirms that pharmacological interventions can fundamentally alter the disease's trajectory.[3]

A Metabolic Approach to the Airway

Obstructive sleep apnea has traditionally been treated as a mechanical problem, managed primarily with continuous positive airway pressure machines that force the throat open during sleep. While highly effective when used consistently, CPAP therapy suffers from notoriously low long-term patient adherence.[2]

Sleep specialists increasingly recognize obesity as the primary metabolic driver of the condition in most patients. Excess adipose tissue—particularly visceral fat and deposits around the pharyngeal walls—physically narrows the airway and compromises its structural integrity during sleep.[3]

Furthermore, excess weight impairs the neuromuscular control required to keep the airway open, creating a cycle where repeated collapses trigger cortisol spikes and worsen metabolic dysfunction. Retatrutide attacks this root cause by targeting three distinct hormone receptors: GLP-1, GIP, and glucagon.[5]

By activating all three pathways simultaneously, the investigational drug drives substantial metabolic changes and weight reduction. In the TRIUMPH-1-OSA trial, which enrolled patients without type 2 diabetes, participants taking the highest 12-milligram dose lost up to 22.2 percent of their body weight over 80 weeks, compared to just 4.8 percent on a placebo.[5]

Measuring the Clinical Impact

The clinical development program nested its sleep apnea evaluations within larger obesity trials, measuring efficacy through the apnea-hypopnea index—a count of how many times a patient's breathing pauses or becomes shallow each hour. Participants entered the trials with severe disease burdens.[2]

Across the two nested studies, patients averaged between 55.9 and 58.6 breathing disruptions per hour at baseline. That translates to nearly one breathing pause every minute of the night, repeatedly jolting the brain awake and driving severe drops in blood oxygen levels.[5]

After 80 weeks of treatment, patients on the 9-milligram and 12-milligram doses saw their index drop by 24.7 and 22.5 events per hour more than the placebo group in the non-diabetic cohort. In the companion trial evaluating patients with type 2 diabetes, the drug reduced events by 13.9 and 15.0 per hour beyond placebo.[2][5]

Beyond simply counting breathing pauses, the medication also significantly reduced sleep apnea–specific hypoxic burden, a critical measure of how much oxygen deprivation a patient experiences overnight. This specific metric is closely associated with the long-term cardiovascular risks that make severe sleep apnea so dangerous.[3]

The safety profile remained consistent with other incretin-based therapies currently on the market. Gastrointestinal adverse events, including diarrhea, nausea, constipation, and dyspepsia, were the most frequently reported side effects and were generally classified as mild to moderate in severity during the dose-escalation phase.[3][5]

The Regulatory Horizon

The new findings position retatrutide to eventually compete directly with Eli Lilly's own Zepbound, a dual-agonist that secured FDA approval for sleep apnea in late 2024. In its pivotal trials, Zepbound cut breathing disruptions by roughly 20 to 24 events per hour over a 52-week period.[2]

While retatrutide's sleep apnea reductions appear roughly comparable to Zepbound's on an absolute basis, its primary differentiator remains the sheer volume of total weight loss achieved over the longer 80-week timeline. However, some experts expected even wider separation between the two blockbuster drugs.[1]

"I think our expectation was, because it is a triple agonist, that we would have had a more significant impact on the weight loss and subsequent AHI, but that wasn't the case," noted Dr. Mariam Louis of the University of Florida. She contextualized the results against existing dual-agonist therapies.[1]

Eli Lilly plans to submit a formal application for retatrutide in the first quarter of 2027, seeking regulatory approval for obesity, osteoarthritis pain, and sleep apnea simultaneously. The company is leveraging a novel basket-trial design to capture multiple adiposity-related disease states in a single development program.[2]

If the FDA grants a standard review timeline, the medication could reach the commercial market by late 2027 or early 2028. Until then, retatrutide remains strictly investigational, and patients are cautioned against seeking unapproved compounded versions marketed online.[3]

For the millions of adults living with obesity-related sleep apnea, the expanding pipeline of incretin therapies represents a fundamental shift in care. Rather than simply managing the mechanical symptoms of airway collapse, clinicians are increasingly equipped to treat the underlying metabolic drivers of the disease.[4]